| Literature DB >> 24898206 |
Maura Barbisin, Silvia Vanni, Ann-Christin Schmädicke, Judith Montag, Dirk Motzkus, Lennart Opitz, Gabriela Salinas-Riester, Giuseppe Legname1.
Abstract
BACKGROUND: Prion diseases are fatal neurodegenerative disorders whose pathogenesis mechanisms are not fully understood. In this context, the analysis of gene expression alterations occurring in prion-infected animals represents a powerful tool that may contribute to unravel the molecular basis of prion diseases and therefore discover novel potential targets for diagnosis and therapeutics. Here we present the first large-scale transcriptional profiling of brains from BSE-infected cynomolgus macaques, which are an excellent model for human prion disorders.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24898206 PMCID: PMC4061447 DOI: 10.1186/1471-2164-15-434
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Correlation between PrP content and duration of clinical phase. Western Blot analysis from PK-treated homogenates of brain samples derived from BSE-infected macaques was performed. The monoglycosylated bands of PrPSc were analyzed densitometrically. Relative amounts of PrPSc from brain homogenates were averaged and correlated to the disease duration.
Figure 2Condition trees of the clustering analysis. The cluster analysis was performed using a hierarchical approach with the average linkage-method (R and Partek® Software, Partek® Inc.): 86 probe sets showed a differential expression with FC ≥ 2. The color represents the level of expression (red: up-regulation, blue: down-regulation) and the sample information is listed across the bottom. The names of the known genes are indicated. More details on all genes are reported in Additional file 1.
List of 3 Ingenuity networks generated by mapping the focus genes that were differentially expressed between non-infected and BSE-infected samples
| ID | Molecules in network | Score | Focus molecules | Top functions |
|---|---|---|---|---|
| 1 | ACVR1C, AKR1D1, Alp, AMPK, Ap1, APOC1, Calcineurin protein(s), CARTPT, caspase, CD3, CHI3L1, Creb, cytochrome C, DACH1, DLK1, ERK, ERK1/2, F13A1, Focal adhesion kinase, GNRH1, HBA1/HBA2, HBB, HDL, hemoglobin, HEY2, HINT1, HIPK2, Ikk (family), IL1, IRF3, Jnk, KDELR2, LDL, LGALS1, Mapk, MEF2C, Mek, MET, MT2A, N4BP1, NADPH oxidase, NGFR, NR4A2, OTX2, P38 MAPK, p85 (pik3r), Pdgf (complex), PDGF BB, PI3K (complex), PI3K (family), PIK3R3, Pkc(s), PLC gamma, PON3, Pro-inflammatory Cytokine, Ras, SERPINA1, SERPINA3, Shc, SHOC2, SLCO1A2, Sos, STK4, TCF, TCR, TNFSF10, TTR, TWIST1, Vegf, WSB1 | 71 | 35 | Tissue Morphology, Cell Death and Survival, Developmental Disorder |
| 2 | ABR, ACTL6B, ARMC6, ASB6, C10orf137, C6orf211, CAMKV, CHMP2A, CLIC4, CLPP, CSNK1G3, CTBP2, DCLRE1A, DDX19B, DGKE, ECT2, FHL3, FLVCR1, GALNTL5, GLOD4, HEATR6, HSP90AA1, HSPA12A, ITFG1, KLF3, KPNA6, MCTS1, MEIG1, METTL7B, MRPL44, MXD3, MYBPC1, NCLN, NIPBL, NOL4, OSBPL10, PCBP3, PLEKHA8, PMM2, POLR2J, PPAP2C, PRCP, PROSC, RAI2, SAP18, SCAND1, SEPT6, SGTB, SMARCC1, SMC3, SPATA22, SPSB3, SRPK3, SSU72, STAG1, TATDN1, TESPA1, TM7SF3, TNK1, TNNI3K, TP53BP1, TRAPPC2L, TRIP12, TUFM, TXNL4A, UBC, ZNF131, ZNF235, ZNF397, ZNF420 | 54 | 28 | Developmental Disorder, Hereditary Disorder, Hematological Disease |
| 3 | 26 s Proteasome, ADCY, AKR1C1/AKR1C2, Akt, APP, ARL4C, Arntl-Clock, AVP, AVPR1B, CACNA1B, CAMKV, CARTPT, CBLN2, CEACAM6, CLDN10, CLOCK, COX4I2, CTF1, DNAJC12, endocannabinoid, estrogen receptor, FAM46A, FSH, GABRE, GNA15, GPR158, GPX1, GPX2, GSK3A, Histone h3, HMGCR, HNF4A, HSPA12A, Insulin, JPH3, KCNC3, KCNS1, LINGO1, LPAR1, LXN, MGAT2, miR-125b-5p (and other miRNAs w/seed CCCUGAG), Mmp, MST1, NFkB (complex), Npff, OPN1LW, PDX1, PIK3R5, Pka, PKM, PLC, Proinsulin, RAB39A, RAI2, RIOK2, RUFY3, SERPINA3, SMAD5, SMC4, SOX7, SYT17, TCF19, Tnfrsf22/Tnfrsf23, TOR2A, tretinoin, trypsin, TXNL4B, ZBTB44, ZFHX3 | 36 | 21 | Cellular Development, Neurological Disease, Skeletal and Muscular System Development and Function |
Names in lowercase are genes/molecules that are not from the DEG list but are associated with some of them within pathways identified by Ingenuity Pathway Knowledge Base (IPKB).
Figure 3Identification of biologically relevant networks. (a) Top ranking network generated by mapping the focus genes that were differentially expressed in infected animals. Pathway analysis based on the Ingenuity Pathway Knowledge Base (IPKB) is shown. Color shading corresponds to the type of dysregulation: red for up-regulated and green for down-regulated genes according to the microarray fold change calculation method. White open nodes are not from the list of 300 DEGs, but are transcription factors that are associated with the regulation of some of these genes identified by IPKB. The shape of the node indicates the major function of the protein. A line denotes binding of the products of the two genes, while a line with an arrow denotes 'acts on'. A dotted line denotes an indirect interaction. (b) Schematic representation of nervous system-related functions for selected DEGs. The most regulated/interesting DEGs were selected and associated to known nervous system-related functions according to the Ingenuity Pathway Knowledge Base (IPKB) software.
Candidate genes for validation
| Gene | Accession number | Known relation with PrP/nervous system | References |
|---|---|---|---|
|
| NM_001195574.1 | Putative role in myelin formation | [ |
|
| NM_001164428.1 | Putative role in intraneuronal oxygen homeostasis, reduced in Alzheimer's and Parkinson's disease | [ |
|
| XM_001083697.2 | PrP/N-CAM complexes found in prion infected N2a cells | [ |
|
| NM_001266910.2 | Mutations related to dopaminergic dysfunction, including Parkinson schizophrenia and depression | [ |
|
| NM_001260999.2 | Depletion of USP16 prevented ATMi from restoring transcription after DSB induction | [ |
| CALB1 | XM_001085269.2 | Plays a protective role in neurodegenerative disorders (depleted in HD) | [ |
| DACH1 | XM_001082371.2 | Required for normal brain development | [ |
| LXN | NM_001266988.1 | Marker for the regional specification of the neocortex | [ |
| PIK3R3 | NM_001266826.1 | Linked to β-amyloid plaque formation in AD brain | [ |
|
| NM_001261034.1 | Possibly related to AD | [ |
|
| NM_001195350.1 | Increased in schizophrenia, SNPs affecting onset and duration of AD | [ |
| TNFSF10 | NM_001266034.1 | Implicated in pathogenesis of MS (causing demyelination) | [ |
|
| NM_001044724.1 | Putative role in intraneuronal oxygen homeostasis, reduced in Alzheimer's and Parkinson's diseases | [ |
| GNRH1 | NM_001195436.1 | Key regulator of the reproductive neuroendocrine system in vertebrates | [ |
|
| NM_001135797 | Putative protective role against prion infection | [ |
|
| AK240617.1 | Binds to ApoE, risk factor for Alzheimer's disease | [ |
| TM7SF3 | XM_001099269.2 | - | - |
| MYBPC1 | XM_001091952.1 | - | - |
|
| NM_001261679 | Amyloid neuropathies, interaction with Aβ | [ |
List of 19 identified genes selected on the basis of fold change value and known relevance for neurodegeneration. Because of very low signal (LXN, PIK3R3, TNFSF10, GNRH1) or lack of reliable sequence data (CALB1, DACH1, TM7SF3, MYBPC1), only 11 genes (in bold) were successfully analyzed. *Macaca fascicularis transcript.
Genes analyzed by RT-qPCR
| Gene | Chromosome | Primer sequence | Amplicon length (bp) | Accession number | |
|---|---|---|---|---|---|
| ACTB | 3 | F: | GTTGCGTTACACCCTTTCTTG | 146 | NM_001033084.1 |
| R: | CTGTCACCTTCACCGTTCC | ||||
| GAPDH | 11 | F: | CCTGCACCACCAACTGCTTA | 74 | NM_001195426.1 |
| R: | CATGAGTCCTTCCACGATACCA | ||||
| AKR1C1 | 9 | F: | CCGCCATATTGATTCTGCTCAT | 132 | NM_001195574.1 |
| R: | TGGGAATTGCACCAAAGCTT | ||||
| HBB | 14 | F: | GTCCTCTCCTGATGCTGTTATG | 102 | NM_001164428.1 |
| R: | TTGAGGTTGTCCAGGTGATTC | ||||
| NCAM1 | 14 | F: | GAGCAAGAGGAAGATGACGAG | 150 | XM_001083697.2 |
| R: | GACTTTGAGGTGGATGGTCG | ||||
| NR4A2 | 12 | F: | CCAGTGGAGGGTAAACTCATC | 145 | NM_001266910.2 |
| R: | AGGAGAAGGCAGAAATGTCG | ||||
| USP16 | 3 | F: | GCAGAACTTGTCACAAACACC | 146 | NM_001260999.2 |
| R: | CTAAAGTAAGAGGGCCTGGAG | ||||
| SAP18 | 17 | F: | GGAAATGTACCGTCCAGCGA | 109 | NM_001261034.1 |
| R: | TGCCCTTCTTTCTAGCTTCTGG | ||||
| SERPINA3 | 7 | F: | GCTGGGCATTGAGGAAGTCT | 123 | NM_001195350.1 |
| R: | GTGCCCTCCTCAGACACATC | ||||
| HBA2 | 20 | F: | CGACAAGAGCAACGTCAAGG | 126 | NM_001044724.1 |
| R: | TCGAAGTGGGGGAAGTAGGT | ||||
| IRF3 | 19 | F: | TGGGTTGTGTTTAGCAGAGG | 90 | NM_001135797 |
| R: | GAAAAGTCCCCAACTCCTGAG | ||||
| APOC1* | 19 | F: | TTCTGTCGATGGTCTTGGAAG | 138 | AK240617.1 |
| R: | CACTCTGTTTGATGCGGTTG | ||||
| TTR | 18 | F: | TCACTTGGCATCTCCCCATTC | 114 | NM_001261679 |
| R: | GGTGGAATAGGAGTAGGGGCT | ||||
Primers (F: forward and R: reverse) used for gene amplification, amplicon length and GenBank® accession numbers of the macaque cDNA sequences used for primer design. All primers were designed according to the genome sequence of Macaca mulatta.
*Apolipoprotein C-I (APOC1) primers were designed according to the genome sequence of Macaca fascicularis because the Macaca mulatta mRNA sequence was not annotated (TSA Macaca mulatta Mamu_450725, accession number: JV045807.1). Homology between the two sequences was 99%.
Figure 4SYBR® Green-based RT-qPCR validation of microarray results. Relative expression levels of 11 genes normalized against GAPDH in BSE-infected cynomolgus macaques.
Figure 5Comparison between SYBR® Green-based and TaqMan® probe-based results. TaqMan® (white) versus SYBR® Green-based (grey) expression levels for each transcript. Both detection systems yielded similar results. Data are normalized against GAPDH. Similar results were obtained with normalization against ACTB (data not shown).
RT-qPCR confirmation of microarray results
| Gene symbol | Microarray fold change | RT-qPCR fold change | |||||
|---|---|---|---|---|---|---|---|
| SYBR® Green | TaqMan® | ||||||
| Min | Max | Mean | FC | P value | FC | P value | |
| AKR1C1 | 2.3 | 2.9 | 2.5 | 1.7 | 0.433 | 2.4 | 0.235 |
|
| −2.2 | −2.6 | −2.4 | 0.2 | 0.020 | 0.3 | 0.021 |
| NCAM1 | −1.1 | 2.5 | −0.3 | 0.5 | 0.160 | - | - |
| NR4A2 | 1.1 | −2.1 | −1.6 | 0.4 | 0.248 | - | - |
| USP16 | −1.2 | −5.5 | −2.6 | 0.5 | 0.308 | - | - |
| SAP18 | −1.2 | −2.6 | −1.7 | 0.8 | 0.393 | - | - |
|
| 10.0 | 16.0 | 13.0 | 18.7 | 0.0001 | 15.3 | 0.0005 |
|
| - | - | - | 0.2 | 0.041 | 0.2 | 0.019 |
| IRF3 | 2.0 | 2.1 | 2.0 | 1.3 | 0.123 | - | - |
|
| 4.3 | - | 4.3 | 6.3 | 0.047 | 6.8* | 0.028* |
|
| 3.1 | - | 3.1 | 7.1 | 0.025 | 5.9 | 0.076 |
Differential expression of selected genes analyzed by microarray and RT-qPCR. For microarray analysis, the lowest (Min), the highest (Max) and the average (Mean) fold change values of all the respective probes are shown. For RT-qPCR analysis, fold change (FC) and statistical significance (p-value) for both SYBR® Green and TaqMan® results are shown. In bold are the genes validated with statistical significance. HBA2 was not present in the array chip.
*Normalization performed vs. ACTB only.